CONAVI MEDICAL CORP. (TSXV: CNVI) (“
CONAVI
MEDICAL” or the “
Company”), a commercial
stage company focused on designing, manufacturing, and marketing
imaging technologies to guide common minimally invasive
cardiovascular procedures, is pleased to announce that it has
engaged the services of ICP Securities Inc.
(“
ICP”) to provide automated market making
services, including use of its proprietary algorithm, ICP Premium™,
in compliance with the policies and guidelines of the TSX Venture
Exchange (“
TSXV”) and other applicable
legislation, and subject to the receipt of approval by the TSXV.
ICP will be paid a monthly fee of C$7,500, plus applicable taxes.
The agreement between the Company and ICP was signed with a start
date of October 22, 2024, and is for four (4) months (the “Initial
Term”) and shall be automatically renewed for subsequent one (1)
month terms (each month called an “Additional Term”) unless either
party provides at least thirty (30) days written notice prior to
the end of the Initial Term or an Additional Term, as applicable.
There are no performance factors contained in the agreement and no
stock options or other equity compensation in connection with the
engagement. ICP has informed the Company that it does not currently
own any securities of the Company; however, ICP and its clients may
acquire an interest in the securities of the Company in the future.
ICP is an arm’s length party to the Company.
ICP’s market making activity will be primarily to correct temporary
imbalances in the supply and demand of the Company’s shares. ICP
will be responsible for the costs it incurs in buying and selling
the Company’s shares, and no third party will be providing funds or
securities for the market making activities.
ABOUT ICP SECURITIES INC.
ICP Securities Inc. is a Toronto based CIRO
dealer-member that specializes in automated market making and
liquidity provision, as well as having a proprietary market making
algorithm, ICP Premium™, that enhances liquidity and quote health.
Established in 2023, with a focus on market structure, execution,
and trading, ICP has leveraged its own proprietary technology to
deliver high quality liquidity provision and execution services to
a broad array of public issuers and institutional investors.
ABOUT CONAVI MEDICAL CORP
Conavi Medical is focused on designing,
manufacturing, and marketing imaging technologies to guide common
minimally invasive cardiovascular procedures. Its patented
Novasight Hybrid™ System is the first system to combine both
intravascular ultrasound (IVUS) and optical coherence tomography
(OCT) to enable simultaneous and co-registered imaging of coronary
arteries. The Novasight Hybrid System has 510(k) clearance from the
U.S. Food and Drug Administration; and regulatory approval for
clinical use from Health Canada, China’s National Medical Products
Administration, and Japan’s Ministry of Health, Labor and Welfare.
For more information, visit http://www.conavi.com/.
Cautionary Statement Regarding
Forward-Looking Information
This news release contains “forward-looking
statements” within the meaning of applicable Canadian and U.S.
securities laws, which reflect the current expectations of
management of Conavi’s future growth, results of operations,
performance and business prospects and opportunities.
Forward-looking statements are frequently, but not always,
identified by words such as “may”, “would”, “could”, “will”,
“anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,
“potential for” and similar expressions, although these words may
not be present in all forward-looking statements. Forward-looking
statements that appear in this release may include, without
limitation, references to Conavi’s plans for the commercialization
of its Novasight Hybrid™ System and to the ability of ICP’s market
making activity to correct temporary imbalances in the supply and
demand of the Company’s shares.
These forward-looking statements reflect
management’s current beliefs with respect to future events, and are
based on information currently available to management that, while
considered reasonable by management as of the date on which the
statements are made, are inherently subject to significant
business, economic and competitive uncertainties and contingencies
which could result in actions, events, conditions, results,
performance or achievements to be materially different from those
projected in the forward-looking statements. Forward-looking
statements involve significant risks, uncertainties and assumptions
and many factors could cause Conavi’s actual results, performance
or achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements. Such factors and assumptions
include, but are not limited to, Conavi’s ability to retain key
personnel; its ability to execute on its business plans and
strategies; and other factors listed in the “Risk Factors” sections
of the joint information circular of Conavi dated August 30, 2024
(which may be viewed at www.sedarplus.com). Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements.
Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions and Conavi has
attempted to identify important factors that could cause actual
actions, events, conditions, results, performance or achievements
to differ materially from those described in forward-looking
statements, Conavi cannot assure prospective investors that actual
results, performance or achievements will be consistent with these
forward-looking statements. Except as required by law, Conavi
expressly disclaims any intention or obligation to update or revise
any forward-looking statements whether as a result of new
information, future events or otherwise. Accordingly, investors
should not place undue reliance on forward-looking statements. All
the forward-looking statements are expressly qualified by the
foregoing cautionary statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
Contacts
Stephen Kilmer Investor Relations (647) 872-4849
stephen.kilmer@conavi.com
Stefano Picone Chief Financial Officer (416)
483-0100
Conavi Medical (TSXV:CNVI)
過去 株価チャート
から 11 2024 まで 12 2024
Conavi Medical (TSXV:CNVI)
過去 株価チャート
から 12 2023 まで 12 2024